CN109715188A - 用于预防或治疗幽门螺杆菌感染的药剂和方法 - Google Patents

用于预防或治疗幽门螺杆菌感染的药剂和方法 Download PDF

Info

Publication number
CN109715188A
CN109715188A CN201780045021.7A CN201780045021A CN109715188A CN 109715188 A CN109715188 A CN 109715188A CN 201780045021 A CN201780045021 A CN 201780045021A CN 109715188 A CN109715188 A CN 109715188A
Authority
CN
China
Prior art keywords
hopq
ceacam
helicobacter pylori
loop
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780045021.7A
Other languages
English (en)
Chinese (zh)
Inventor
阿娜希塔·贾瓦希里
托比亚斯·克鲁泽
马库斯·格哈德
伯恩哈德·B·辛格尔
丹尼尔·霍恩伯格
汗·雷莫特
马蒂亚斯·曼
费利克斯·迈斯纳
斯特芬·巴克特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technische Universitaet Muenchen
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Technische Universitaet Muenchen
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technische Universitaet Muenchen, Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Technische Universitaet Muenchen
Publication of CN109715188A publication Critical patent/CN109715188A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/121—Helicobacter (G); Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/062—Gastritis or peptic ulcer disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
CN201780045021.7A 2016-07-20 2017-07-20 用于预防或治疗幽门螺杆菌感染的药剂和方法 Pending CN109715188A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16180430.7A EP3272354A1 (en) 2016-07-20 2016-07-20 Agents and methods for the prevention or treatment of h. pylori infections
EP16180430.7 2016-07-20
PCT/EP2017/068297 WO2018015468A1 (en) 2016-07-20 2017-07-20 Agents and methods for the prevention or treatment of h. pylori infections

Publications (1)

Publication Number Publication Date
CN109715188A true CN109715188A (zh) 2019-05-03

Family

ID=56511365

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780045021.7A Pending CN109715188A (zh) 2016-07-20 2017-07-20 用于预防或治疗幽门螺杆菌感染的药剂和方法

Country Status (8)

Country Link
US (2) US11471532B2 (https=)
EP (2) EP3272354A1 (https=)
JP (1) JP7189124B2 (https=)
CN (1) CN109715188A (https=)
AU (1) AU2017300021B2 (https=)
CA (1) CA3030787A1 (https=)
MX (1) MX2019000428A (https=)
WO (1) WO2018015468A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111675750A (zh) * 2020-06-11 2020-09-18 中国药科大学 针对癌胚抗原相关黏附分子ceacam的肿瘤靶向肽及其应用
CN112322693A (zh) * 2020-11-24 2021-02-05 上海健康医学院 一种巨噬细胞中幽门螺丝杆菌的标记方法
CN113388616A (zh) * 2021-07-27 2021-09-14 中国海洋大学 特异性结合幽门螺旋杆菌的核酸适配体、生物元件、生物传感器及检测方法
CN115515625A (zh) * 2020-05-11 2022-12-23 伊穆诺比奥股份公司 与人类ceacam1/3/5特异性结合的新抗体及其用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3272354A1 (en) 2016-07-20 2018-01-24 Technische Universität München Agents and methods for the prevention or treatment of h. pylori infections
US11150237B2 (en) 2018-03-30 2021-10-19 The Regents Of The University Of California Patient-specific biomarkers of Escherichia coli invasion in inflammatory bowel disease
CN108794585A (zh) * 2018-05-28 2018-11-13 广东工业大学 一种抗幽门螺杆菌的卵黄抗体制备方法及应用
KR102370176B1 (ko) * 2020-03-02 2022-03-03 한국생명공학연구원 HopQ를 포함하는 암전이 억제용 조성물
CN118480136B (zh) * 2024-06-19 2025-01-14 南京澄实生物医药科技有限公司 一种预防和治疗金黄色葡萄球菌感染的免疫原性组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576244B1 (en) * 1998-06-19 2003-06-10 Acambis, Inc. LT and CT in parenteral immunization methods against helicobacter infection

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR003125A1 (es) 1995-06-01 1998-07-08 Astra Ab Antigenos bacterianos para el diagnostico de infecciones con helicobacter pylori, una molecula de adn que lo codifica, un vector, una celula huesped,procedimiento para producir el polipeptido, composiciones para vacunas adecuadas para uso terapeutico y profilactico, el uso del polipeptido en la
US20050063987A1 (en) 1996-07-26 2005-03-24 Chiron Behring Gmbh & Co Proteins, in particular membrane proteins, of Helicobacter pylori, their preparation and use
US20020151462A1 (en) 1998-02-19 2002-10-17 Ling Lissolo Helicobacter pylori membrane proteins
SE9801287D0 (sv) 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
SE9801288D0 (sv) 1998-04-14 1998-04-14 Astra Ab Vaccine delivery system and metod of production
WO2001083531A1 (en) 2000-04-27 2001-11-08 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying helicobacter antigens
GB0010371D0 (en) 2000-04-29 2000-06-14 Astrazeneca Ab Helicobacter pylori antigens
EP1301204A1 (en) 2000-07-05 2003-04-16 Merieux OraVax SNC Immunological combinations for prophylaxis and therapy of helicobacter pylori infection
DE10032538A1 (de) 2000-07-05 2002-01-17 Max Planck Gesellschaft Vakzine gegen Helicobacter pylori
WO2002066501A2 (en) 2001-01-02 2002-08-29 Hybrigenics PROTEIN-PROTEIN INTERACTIONS IN $i(HELICOBACTER PYLORI)
JP2005506322A (ja) 2001-08-31 2005-03-03 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉワクチン接種
JP3823268B2 (ja) 2002-05-30 2006-09-20 独立行政法人科学技術振興機構 ヘリコバクター・ピロリの細胞死誘導剤
EP1599164B1 (en) 2003-02-03 2015-04-08 Cerebus Biologicals, Inc. Methods for treating, preventing and detecting helicobacter infection
EP1622933A2 (en) 2003-04-22 2006-02-08 Intercell AG H. pylori antigens
US20070042448A1 (en) 2005-06-02 2007-02-22 Institute Pasteur Use of enzymes from Helicobacter pylori as therapeutical targets
CN100460013C (zh) 2006-09-05 2009-02-11 重庆康卫生物科技有限公司 口服重组幽门螺杆菌疫苗及其制备方法
EP1913955A1 (en) 2006-10-19 2008-04-23 Gerhard, Markus Novel method for treating H.pylori infections
SI22889A (sl) 2008-10-28 2010-04-30 Kemijski inštitut Himerni flagelini za cepiva
WO2011018779A1 (en) 2009-08-13 2011-02-17 The Provost, Fellows and Scholars of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin Modified helicobacter protein
WO2011081598A1 (en) 2009-12-28 2011-07-07 Mivac Development Aktiebolag New antigens for use in a vaccine against h.pylori infection
CN101955545B (zh) 2010-09-07 2012-07-04 四川万可泰生物技术有限责任公司 一种多靶点重组基因及其蛋白在防治幽门螺旋杆菌感染中的应用
EP2844301A2 (en) 2012-05-04 2015-03-11 Ineb-instituto de Engenharia Biomédica Microspheres for treating helicobacter pylori infections
EP3272354A1 (en) 2016-07-20 2018-01-24 Technische Universität München Agents and methods for the prevention or treatment of h. pylori infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576244B1 (en) * 1998-06-19 2003-06-10 Acambis, Inc. LT and CT in parenteral immunization methods against helicobacter infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LEA CHARLOTTE HOLSTEN: "Charakterisierung neuer Adhäsinrezeptoren von Helicobacter pylori und deren Rolle bei der Translokation des Cytotoxins CagA", 《慕尼黑大学论文》 *
VERENA KÖNIGER: "CEACAMs as novel receptors for Helicobacter pylori outer membrane protein HopQ", 《慕尼黑大学论文》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115515625A (zh) * 2020-05-11 2022-12-23 伊穆诺比奥股份公司 与人类ceacam1/3/5特异性结合的新抗体及其用途
CN111675750A (zh) * 2020-06-11 2020-09-18 中国药科大学 针对癌胚抗原相关黏附分子ceacam的肿瘤靶向肽及其应用
CN115583987A (zh) * 2020-06-11 2023-01-10 中国药科大学 针对癌胚抗原相关黏附分子ceacam的肿瘤靶向肽及其应用
CN115583987B (zh) * 2020-06-11 2025-02-18 中国药科大学 针对癌胚抗原相关黏附分子ceacam的肿瘤靶向肽及其应用
CN112322693A (zh) * 2020-11-24 2021-02-05 上海健康医学院 一种巨噬细胞中幽门螺丝杆菌的标记方法
CN113388616A (zh) * 2021-07-27 2021-09-14 中国海洋大学 特异性结合幽门螺旋杆菌的核酸适配体、生物元件、生物传感器及检测方法
CN113388616B (zh) * 2021-07-27 2022-04-26 中国海洋大学 特异性结合幽门螺旋杆菌的核酸适配体、生物元件、生物传感器及检测方法

Also Published As

Publication number Publication date
AU2017300021B2 (en) 2024-04-11
JP7189124B2 (ja) 2022-12-13
MX2019000428A (es) 2019-06-10
US20210008207A1 (en) 2021-01-14
US20230087805A1 (en) 2023-03-23
JP2019529346A (ja) 2019-10-17
AU2017300021A1 (en) 2019-01-24
EP3487517A1 (en) 2019-05-29
EP3487517B1 (en) 2023-04-05
WO2018015468A1 (en) 2018-01-25
CA3030787A1 (en) 2018-01-25
US11471532B2 (en) 2022-10-18
US12558425B2 (en) 2026-02-24
EP3272354A1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
US12558425B2 (en) Agents and methods for the prevention or treatment of H. pylori infections
JP6832901B2 (ja) Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
Tegtmeyer et al. Toll-like receptor 5 activation by the CagY repeat domains of Helicobacter pylori
JP4763210B2 (ja) ナイセリアのタンパク質の異種発現
KR20140019848A (ko) 면역원성 조성물
US10420828B2 (en) Targets of acinetobacter baumannii
Kumar et al. Structural analysis and cross-protective efficacy of recombinant 87 kDa outer membrane protein (Omp87) of Pasteurella multocida serogroup B: 2
Tavano et al. Mapping of the Neisseria meningitidis NadA cell-binding site: relevance of predicted α-helices in the NH2-terminal and dimeric coiled-coil regions
CN108495650B (zh) 幽门螺杆菌疫苗
US20230241197A1 (en) Protein molecule useful for anti-pseudomonas aeruginosa vaccine
CN117979992A (zh) 钩端螺旋体毒力调节蛋白及其用途
WO2007049770A1 (ja) 緑膿菌の外膜タンパク質ｐａ５１５８
HK40106181A (zh) 鈎端螺旋体毒力调节蛋白及其用途
Backert et al. Virulence factors of Helicobacter pylori.
WO2026082115A1 (zh) B群脑膜炎球菌的抗原融合蛋白组合及其用途
Panangala et al. Organization and sequence of four flagellin‐encoding genes of Edwardsiella ictaluri
EP4731641A1 (en) Bio-engineered flagellin-derived scaffold backbone and uses thereof
CN120265308A (zh) 用于治疗生物膜和中性粒细胞胞外陷阱形成的组合物和方法
Gray-Owen et al. Slam is an outer membrane protein that is required for the surface display of lipidated virulence factors in Neisseria
Williams The DamX cell division protein of Escherichia coli: Identification of amino acid residues critical for septal localization and peptidoglycan binding
Tosi Structural studies of virulence factors from the bacterium Helicobacter pylori
Tosi Études Structurales de Facteurs de Virulence de la Bactérie Helicobacter Pylori

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination